Targeting SLMAP-ALK—a novel gene fusion in lung adenocarcinoma

• DOI: 10.1101/mcs.a003939
• Publication Date: 2019-06-03T18:45:26Z
• Authors: Carlos Pagan; Subit Barua; Susan J. Hsiao; Mahesh Mansukhani; Anjali Saqi; Vundavalli Murty; Helen Fernandes
• Keywords: Targeted Therapy

Assessment of ALK gene rearrangements is strongly recommended by the Molecular Testing Guideline for Selection Lung Cancer Patients proposed IASLC, AMP, and CAP at time diagnosis patients with advanced stage disease. Non-small-cell lung cancer (NSCLC) or resulting fusion proteins have been, most part, successfully targeted tyrosine kinase inhibitors (TKIs). The frequent rearrangement, EML4-ALK oncogenic fusion, has more than 10 distinct variants, each a discrete breakpoint in EML4 . Recent studies suggested that variants may differential responses to TKIs. Additionally, non-EML4-ALK fusions result from diverse 5′ partners could possibly varied biologic clinical implications their therapeutic outcomes NSCLC. Existing literature documents least 20 non-EML4 ALK, responsiveness crizotinib ranges increased sensitivity resistance. This underscores importance identifying precise partner before initiation therapy. Herein we report identification novel SLMAP-ALK patient